Astec LifeSciences Limited — Results, 10-02-2025: Integrated Filing- Financial

Astec LifeSciences has announced a board meeting to discuss the financial results for the quarter and nine months ended December 31, 2024. The company reported a revenue from operations of ₹93.86 crore, with total income of ₹95.77 crore. However, it incurred a net loss of ₹40.37 crore during this period. The current ratio stands at 0.79, indicating liquidity concerns, while the debt-to-equity ratio is at 2.05, signaling high leverage. This financial performance may weigh on investor sentiment, suggesting caution due to ongoing operational challenges and significant losses.